Rafael and Curesponse to Collaborate on Precision Oncology Platform
04 févr. 2022 08h00 HE
|
Curesponse
HAIFA, Israel, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Curesponse (www.curesponse.com) and Rafael (https://www.rafael.co.il/) to collaborate on integrating Artificial Intelligence capabilities in...
Cellworks Singula™ Delivers Superior OS and DFS Predictions for Brain Cancer Patients in myCare-022-03 Clinical Trial
04 juin 2021 09h00 HE
|
Cellworks Group, Inc.
SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced...
Cellworks Singula™ Accurately Predicts Clinical Outcome from Treatments in Patients with NSCLC
04 juin 2021 09h00 HE
|
Cellworks Group, Inc.
SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced...
Cellworks CBM Identifies Genomic Signatures Impacting HOXA Regulation that Determine Response for AML Patients with Monosomy 7
07 déc. 2020 11h00 HE
|
Cellworks Group, Inc.
myCare-021-04 study finds genetic signatures associated with 100% remission rate fromAML induction therapy despite presence of Monosomy 7 SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE)...
Cellworks Personalized Biosimulation Clinical Trials Achieve 90% Therapy Response Prediction Accuracy for AML and MDS Patients
07 déc. 2020 11h00 HE
|
Cellworks Group, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced...
Cellworks Personalized Biosimulation Clinical Trial Predicted ATO and ATRA Therapy Response in APL Patients with 93% Accuracy
07 déc. 2020 11h00 HE
|
Cellworks Group, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced...
Cellworks CBM Biosimulation Identifies Genomic Causes for Induction Failure in AML Patients and Suggests Alternative Therapies
07 déc. 2020 11h00 HE
|
Cellworks Group, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced...
myCare Clinical Studies Show Cellworks Singula™ Achieves Superior Therapy Response Predictions for Brain Cancer Patients
29 mai 2020 08h00 HE
|
Cellworks Group, Inc.
SOUTH SAN FRANCISCO, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced...
Cellworks Singula™ Predicts Personalized Therapy Responses for AML and MDS Patients with Higher Accuracy than Physician Prescribed Treatments
14 mai 2020 08h00 HE
|
Cellworks Group, Inc.
SOUTH SAN FRANCISCO, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced...
Cellworks Singula™ Predicts Personalized Therapy Responses for Pancreatic Cancer Patients with 94% Accuracy
14 mai 2020 08h00 HE
|
Cellworks Group, Inc.
myCare Study Shows Cellworks Multi-omics Biosimulation is a Superior Predictor of Therapy Response in PDAC Patients Compared to Physician Prescribed Treatment SOUTH SAN FRANCISCO, Calif., May ...